TNF and psoriasis: In an open-label proof-of-concept trial, treatment with RGRN - 305 led to marked clinical improvement in a subset of patients with moderate-to-severe psoriasis, accompanied by molecular and histological normalization of key inflammatory pathways, including TNF-α, IL - 23, and IL - 17A signaling (11).